Bozic Carmen 4

What Happened
Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals (VRTX), disposed of 2,145 shares on February 10, 2026 to satisfy tax obligations tied to an equity transaction. The shares were valued at $468.41 each, totaling $1,004,739. This was a tax-withholding/net-settlement action (transaction code F), not an open-market sale that signals a cash exit.

Key Details

• Transaction date: 2026-02-10; filing date: 2026-02-12 (filed within the typical 2-business-day Form 4 window).
• Price per share: $468.41; shares surrendered: 2,145; total value: $1,004,739.
• Transaction code: F — payment of exercise price or tax liability (shares disposed to cover taxes).
• Shares owned after the transaction: not specified in the provided filing.
• No indication in this filing of a 10b5-1 plan or an open-market sale; this appears to be routine tax withholding.

Context
An F-code transaction typically occurs when shares issued on exercise or vesting are withheld or surrendered to satisfy tax withholding; it is administrative and does not necessarily reflect the insider’s view on the company’s stock. Purchases generally carry more interpretive weight for bullish signals; tax-withholding disposals are common and routine.